Analyst Ratings For NKTR – Nektar Therapeutics (NASDAQ:NKTR)
Today, HC Wainwright reiterated its Buy rating on NKTR – Nektar Therapeutics (NASDAQ:NKTR) with a price target of $125.00.
Some recent analyst ratings include
- 4/2/2018-HC Wainwright Reiterated Rating of Buy .
- 3/2/2018-Cowen Reiterated Rating of Buy.
- 11/13/2017-JPMorgan Chase Reiterated Rating of Positive .
Recent Insider Trading Activity For NKTR – Nektar Therapeutics (NASDAQ:NKTR)
NKTR – Nektar Therapeutics (NASDAQ:NKTR) has insider ownership of 5.44% and institutional ownership of 96.22%.
- On 3/7/2018 Christopher A Kuebler, Director, sold 40,000 with an average share price of $97.60 per share and the total transaction amounting to $3,904,000.00.
- On 3/7/2018 John Nicholson, COO, sold 220,144 with an average share price of $99.27 per share and the total transaction amounting to $21,853,694.88.
- On 2/16/2018 Gil M. Labrucherie, CFO, sold 3,477 with an average share price of $82.94 per share and the total transaction amounting to $288,382.38.
- On 2/16/2018 Howard W Robin, CEO, sold 12,788 with an average share price of $82.94 per share and the total transaction amounting to $1,060,636.72.
- On 2/16/2018 Jillian B. Thomsen, CAO, sold 2,545 with an average share price of $82.94 per share and the total transaction amounting to $211,082.30.
- On 2/16/2018 John Nicholson, COO, sold 4,879 with an average share price of $82.94 per share and the total transaction amounting to $404,664.26.
- On 2/16/2018 Stephen K Doberstein, SVP, sold 2,426 with an average share price of $82.94 per share and the total transaction amounting to $201,212.44.
Recent Trading Activity for NKTR – Nektar Therapeutics (NASDAQ:NKTR)
Shares of NKTR – Nektar Therapeutics closed the previous trading session at with 208350 shares trading hands.